Accelerate the discovery of new medicines, without exposing sensitive data.
“How do you scale AI in sectors where data is sensitive, regulated and cannot be shared?”
This is today the main bottleneck for unlocking innovation in healthcare and pharma, with direct impact on human health. The ConvergeLab Summit connects science, regulation and market around a shared agenda.
IA Privada · Private AI ◆ Computação Federada · Federated Computing ◆ Soberania de Dados · Data Sovereignty ◆ Pharma 4.0 ◆ Saúde Digital · Digital Health ◆ LGPD ◆ Deep Tech ◆ Drug Discovery ◆ Open Innovation ◆ IA Privada · Private AI ◆ Computação Federada · Federated Computing ◆ Soberania de Dados · Data Sovereignty ◆ Pharma 4.0 ◆ Saúde Digital · Digital Health ◆ LGPD ◆ Deep Tech ◆ Drug Discovery ◆ Open Innovation ◆
01 — The Summit
Where open innovation meets data security .
02
Days of immersion
Oct 22 — 23
40+
Expected leaders
Keynotes & panels
06
Thematic tracks
From research to market
∞
Possible connections
Targeted matchmaking
1.1 — Audiences
Five communities, one shared agenda.
01
Startups & Deep Techs
Seeking technological, regulatory and commercial validation.
02
Pharmaceutical Industry
Looking for new routes of open and regulated innovation.
03
Hospitals, Labs & RTOs
Capable of generating, qualifying and validating clinical data.
04
Regulators & Government
Building safe environments for innovation in healthcare.
05
Investors, Funds & CVCs
Reducing technological, regulatory and market risk.
02 — Tracks
Six tracks where science, regulation and market meet.
Each track is a research, regulatory and business agenda. Decision-makers, researchers and investors share the same space, for the first time in Brazil.
01
Phytotherapy, biodiversity and public health
Connecting Brazil's natural heritage, science and new therapeutic routes.
02
Public policy and national health systems
How public systems can catalyze regulated innovation at scale.
03
Innovation and technology for public health
AI, clinical data and infrastructure for a digital public health system.
04
Production and local arrangements
Industrial sovereignty, the healthcare economic complex and regional RTOs.
05
Access, financing and innovation funding
BNDES, Finep, FAPs, venture capital and shared-risk models.
06
Regulation and tech incorporation
ANVISA, Conitec, LGPD, intellectual property and regulatory AI.
Featured tags ·Explainable AILGPDRegulatory validationBioequivalenceHealth sovereigntyCEISNIBPDPData spacesRegulatory sandboxRWDPharma 4.0
03 — Program
Two days to connect, validate and move the agenda.
A high-level program on federated infrastructure, AI for the pharmaceutical industry and new models of collaboration across science, business and regulation.
Preliminary program · updated July 13, 2026
08:30
— 09:30
08:30— 09:30
Opening
Registration, welcome coffee and institutional opening
Program introduction and Summit kick-off, broadcast simultaneously in the auditorium and lounge.
09:30
— 10:10
09:30— 10:10
TalkConfirmed
Federated data ecosystems for industry
European lessons for Brazilian value chains.
Kai Lindow · Fraunhofer IPK
10:10
— 10:50
10:10— 10:50
TalkIn curation
What industry learned from Europe’s largest federated drug discovery consortium
10:50
— 11:30
10:50— 11:30
PanelIn curation
Round table · Federated computing consortia
Applying European experience to collaborative models for pharmaceutical innovation in Brazil.
Kai Lindow · Fraunhofer IPK Ecosystem guests
Session context
The discussion brings together federated consortia, industrial policy and startups to address governance, cooperation and scale without centralising sensitive data.
11:30
— 12:30
11:30— 12:30
TalkConfirmed
In silico software and AI: generating multidata for new medicines
How software, modelling and AI integrate multiple data sources throughout medicine development.
Cocrystal AI and the challenges of Brazil’s public health system
Drug discovery, artificial intelligence and federated computing for pharmaceutical innovation.
Pollyana Firmino · InsilicAll / NanoBusiness
15:00
— 16:00
15:00— 16:00
TalkIn curation
Federated computing consortia in Brazil
Opportunities for industry, RTOs and deep-tech startups to collaborate without centralising sensitive data.
16:00
— 17:00
16:00— 17:00
TalkIn curation
Thematic session · to be announced
17:00
— 18:00
17:00— 18:00
Connections
Strategic matchmaking & Startup Arena
Industry, RTOs, investors, startups and regulators in a curated round of meetings and pitches.
18:00
18:00
Closing
End of day
08:30
— 09:10
08:30— 09:10
TalkConfirmed
Data Spaces and HPC as a Service
Federated infrastructure for AI in regulated pharmaceutical value chains.
Ernesto Lembcke · GIZ
09:10
— 09:50
09:10— 09:50
TalkConfirmed
Synchrotron-as-a-Service for the pharmaceutical industry
Access to advanced characterisation and high-resolution data for pharmaceutical research and development.
Mateus Cardoso · Sirius / LNLS / CNPEM
09:50
— 10:30
09:50— 10:30
PanelConfirmed
Round table · Advanced infrastructure as a service
Data Spaces, HPC and synchrotron light as infrastructure for pharmaceutical innovation.
Ernesto Lembcke · GIZ Mateus Cardoso · LNLS / CNPEM Ronaldo Pedro · ConvergeLab
Session context
The panel links computational and characterisation infrastructure to AI drug discovery, deformulation and solid-form analysis, exploring new collaboration models across industry, government and RTOs.
10:30
— 11:30
10:30— 11:30
TalkConfirmed
From Sirius to PolymorphID
Federated AI and Synchrotron-as-a-Service for advanced pharmaceutical data analysis.
Ronaldo Pedro · ConvergeLab
11:30
— 13:00
11:30— 13:00
Networking
Executive lunch & targeted networking
13:00
— 13:30
13:00— 13:30
TalkConfirmed
Multidata: secure sharing to accelerate pharmaceutical solutions
Secure integration of multiple data sources to accelerate technology solutions for the pharmaceutical sector.
A public-health and digital-transformation specialist with international experience in citizen-centred public systems.
Read full bio+
An MSc graduate in Public Health from the London School of Hygiene and Tropical Medicine, he works across public health, migration and digital transformation. After roles in Mozambique, Peru, Kenya and Germany, he is now a Technical Advisor to GIZ’s German–Brazilian Digital Dialogue in Brasília, covering digital health, digital public infrastructure, emerging technologies and information integrity.
He leads the strategy for digital technologies that create industrial value at Fraunhofer IPK.
Read full bio+
Dr. Kai Lindow is an expert in digital technologies with a focus on data and model integration, digital ecosystems, data spaces and AI-driven solutions – always with an eye on business potential. For over a decade, he has been developing systemic approaches to make products and processes more efficient and resource-saving. After studying mechanical engineering in Berlin and Stockholm, he completed his PhD on “Knowledge-based development of sustainable products” at TU Berlin. Following his post-doctoral research at the interface of engineering and computer science, he became head of the Information and Process Control department at Fraunhofer IPK in Berlin, where he now serves as Director of Digital Engineering. He is actively involved in industrial and scientific working groups and a frequent voice on industry and research panels.
He develops advanced synchrotron-light techniques to investigate high-resolution phenomena at the nano–bio interface.
Read full bio+
At Sirius, he leads the development and application of synchrotron-light techniques for nanomedicine, nanotoxicology, health and environmental research. His strategic work spans the Sibipiruna, Timbó and Hibisco beamlines, integrated into Project Orion and high-containment environments for the safe study of complex biological systems.
A Medicinal Chemistry PhD with more than a decade of work in AI, predictive modelling and regulatory toxicology.
Read full bio+
He has over ten years of experience in predictive modelling, analytics and data science for pharmaceutical innovation and regulatory toxicology. He is founder and CTO of NanoBusiness and InsilicAll, a Latin American platform combining artificial intelligence and computational methods to accelerate small molecules, protein therapeutics and toxicological safety assessments.
An R&D executive with 18 years of experience across the pharmaceutical and chemical industries.
Read full bio+
A chemistry professional with 18 years of experience in Research, Development and Innovation. He has led multidisciplinary technical teams, new-product development and global strategic projects. As CEO of InsilicAll, he drives the company’s growth and international expansion by connecting deep chemistry expertise with artificial intelligence.
For more than 20 years he has turned nanotechnology, biotechnology and AI into pharmaceutical solutions and deep-tech ventures.
Read full bio+
He has over 20 years of experience in research, development and innovation focused on advanced materials and pharmaceutical solutions. He is founder and Principal Investigator at NanoBusiness and ConvergeLab Venture Builder, de-risking deep-tech opportunities for investors, researcher-entrepreneurs and startups. He also teaches Innovation and Entrepreneurship at UFRJ.
An interdisciplinary researcher in biomolecular physics, nanoscience, crystal engineering and drug development.
Read full bio+
Her pharmaceutical-science work includes experience at the University of São Paulo and the University of Bologna. She took part in the Royal Academy of Engineering’s LIF Global 2026 programme. Her research covers the development, synthesis and characterisation of new solid forms of active pharmaceutical ingredients, crystallography and nanoscience applied to medicine.
Connect your brand to the new architecture of AI, federated computing and secure data collaboration, at the event shaping the infrastructure of the next decade.
Naming sponsor
IMaster
Tier 01 · 04
Architecture Partner
For organizations seeking to be architects of the new era of health. Positions the brand as a central partner of the AI and sensitive-data infrastructure.
Ideal for organizations focused on brand association and strengthening institutional presence within the open-innovation and secure-collaboration agenda.
Silver Sponsor brand status
Inclusion on the official site
Exposure in institutional materials
Ticket allocation
Participation in networking sessions
Option to distribute institutional materials
Matchmaking participation subject to availability (*)
(*)Matchmaking is subject to confirmation of at least one Gold and one Master sponsorship.
◆
5.1 — Special activations
Experiences that turn visibility into relationships.
Beyond the main tiers, the event offers specific activations to expand relationships, technology demos and business generation.
"
Connecting those with challenges, data, technology and the power to validate.
Core message · 06
I
Matchmaking
Strategic connection round between startups, industry, investors and institutions.
01 / 06
II
Federated Regulatory AI
AI-driven pharmaceutical safety and compliance assessment in a federated network. Industry and labs validate together, with sensitive data never leaving its source.
02 / 06
III
Federated Discovery AI
Drug and solid-form discovery with models co-trained across institutions. The dataset is never shared, only the learning.
03 / 06
IV
Regulatory Tables
Strategic debate with regulators and specialists on legal and technical paths.
04 / 06
V
Networking Lounge
Premium space for closing deals and private conversations.
